HALB

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Oct 27, 2025

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies Halberd Demonstrates NeuroSense AI FeasibilityHalberd Corporation successfully validated its NeuroSense AI system in a live demonstration, showcasing advanced multi-modal behavioral analysis technology designed to revolutionize traumatic brain injury (TBI) research and neurological diagnostics. AI-Powered Insights into Brain and Behavioral FunctionThe NeuroSense AI...

Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment

Sep 29, 2025

First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications Jackson Center, PA, September 29, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic brain...

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

May 28, 2025

Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa., May 28, 2025 - PRISM MediaWire - Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney...

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects

Mar 17, 2025

The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! Key Points: Athena GTX Secures $2.87 Million U.S. Government Contract for Smart Critical Care System Athena GTX has been awarded a $2,866,000 final development contract from the U.S. government for its Smart Autonomous Critical Care System (S-ACCS). This milestone strengthens its position in wireless patient monitoring and life-saving medical technology, with additional government contract awards currently...

Halberd Update on WatchDawg® PTSD Treatment

Dec 2, 2024

Next Phase Pilot Study Jackson Center, PA, December 2, 2024 - PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software...

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Oct 1, 2024

Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation....

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Sep 11, 2024

Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA., September 11, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology...

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Sep 9, 2024

Early Pilot Study Data from Veteran Volunteers is Compelling - Part B Jackson Center, PA September 9, 2024 – PRISM MediaWire - Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week’s Press release, Part A. This Part B supplements that release of a few days ago. As always reach out to us if you have any comments or thoughts. Good or bad, we appreciate them! The PTSD market is evolving. It is also...

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Sep 4, 2024

Early Pilot Study Data from Veteran Volunteers is Compelling Jackson Center, PA September 4, 2024 - PRISM MediaWire - Halberd Corporation (OTC: HALB) To our shareholders: As promised, this is the second of three Press Releases on our recent progress. If you have not had a chance to review that last one, on the good news on our Tri-aX™ Nasal Spray for TBI, please do. This one follows the same process. This Press Release is focused on LDN+, as related to Post Traumatic Stress Disorder (PTSD) and...

Halberd Corp. Issues Letter to Shareholders

Aug 26, 2024

JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp. - Taking a Moment to Recenter Our Technical Progress Introducing Tri-ax™ TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing...

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Jul 24, 2024

Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented: “In the early stages of our Phase II studies, we focused on assessing the efficacy of our innovative Tri-AxTM nasal spray in...

NEWSROOM

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment

Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects

Halberd Update on WatchDawg® PTSD Treatment

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

Halberd Corp. Issues Letter to Shareholders

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

Contact Us